Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Osteitis Deformans × Trastuzumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 100 HER2-positive Breast Cancer 7 Stomach Neoplasms 5 Neoplasms 4 Neoplasm Metastasis 4 Inflammatory Breast Neoplasms 3 Esophageal Neoplasms 3 Adenocarcinoma Of Esophagus 3 Invasive Breast Cancer 2 HER2-positive Metastatic Breast Cancer 2 HER2-positive Early Breast Cancer 2 Colonic Neoplasms 2 Biliary Tract Neoplasms 2 Solid Tumors 1 Resectable HER2-positive Breast Cancer 1 Patient Preference 1 Pathologic Complete Response 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Osteitis Deformans 1 HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients 1 HER2-positive Gastric Cancer 1 HER2-positive Carcinoma of Breast 1 HER2-positive Advanced Breast Cancer 1 HER2+ Breast Cancer 1 HER2 Positive Early or Locally Advanced Breast Cancer 1 HER2 Positive Early Breast Cancer 1 Endometrial Neoplasms 1 Early-stage or Locally Advanced HER2-positive Breast Cancer 1 Early or Locally Advanced HER2-positive Breast Cancer 1 Colorectal Neoplasms 1

Interventions

ribociclib 1 Trastuzumab 1 Paclitaxel 1 Letrozole 1 Lapatinib 1 Goserelin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00553358 2021-09-21

Neo ALTTO

Novartis

Phase 3 Completed

455 enrolled 34 charts

Breast Neoplasms, Osteitis Deformans

Data powered by HemOnc (CC BY 4.0) Colophon ⚡